Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Şahin, Mehmet; Aydıntuğ, Olcay; Tunc, Sevket Ercan; Tutkak, Hüseyin; Nazıroğlu, Mustafa

doi:10.1016/j.clinbiochem.2006.09.003

Cited by 18 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recent studies showed the proapoptotic role of IL-18 through Fas/Fas ligand pathway [12,13,15]. Our results supported the earlier studies that revealed significant increase in serum levels of IL-18 [8][9][10][11] or sFas [5][6][7]22] in lupus patients in comparison with controls; however, there are still controversies on this issue, Sahin M et al [2] reported decreased serum levels of sFas in lupus patients; however, they have also referred to other studies reporting normal or high levels of sFas in lupus patients. These controversies may be due to sampling sizes or inclusion criteria for patients and the stages of disease activities.…”

Section: Discussionsupporting

confidence: 95%

“…This can be explained by inactive disease state in some patients who were taking maintenance immunomodulatory drugs due to major organ involvement. These results support Sahin et al [2] study that reports no significant difference between serum sFas levels in patients on glucocorticoid or immunomodulatory therapies in different autoimmune diseases and the patients who were not treated with these drugs. In other words, these drugs may reduce serum levels of sFas and IL-18 via apoptosis and cytokine release modulation before decreasing the disease activity.…”

Section: Discussionsupporting

confidence: 93%

“…Fas(Apo/1-CD95) and Fas ligand are essential factors in the activated induced cell death, and any dysfunction in this system will lead to a breakdown in peripheral tolerance and induction of an autoimmune phenomenon [2]. Increased serum concentrations of soluble Fas ligand and/or soluble Fas antigen (sFas) are quite often a remarkable peculiarity observed in lupus erythematosus disease [2][3][4]. With the assumption of suppressive effects of sFas on Fas-mediated apoptosis, it was proposed that sFas helps autoreactive thymocytes escaping the negative selection by bearing transmembrane Fas antigen on their surface.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

et al. 2010

View full text Add to dashboard Cite

Recent researches suggest that imbalance in apoptotic process may lead to susceptibility to systemic lupus erythematosus (SLE). Production of pro-inflammatory cytokines, such as IL-18, has important role in autoimmune process in lupus. There are cumulative data on the pro-apoptotic role of IL-18, in the Fas-mediated apoptosis. Soluble Fas (Apo/1-CD95) is a marker of apoptosis that appears to increase in serum of SLE patients. Previous studies demonstrated increasing serum concentrations of soluble Fas (sFas) and IL-18 in SLE. To assess the correlation between serum concentrations of sFas and IL-18 in SLE patients, 114 SLE patients were selected randomly at the different stages of disease activity according to SLEDAI2K. IL-18 and sFas serum concentrations were compared in patients and fifty randomly selected healthy volunteers. The correlations of IL-18 and sFas serum concentrations with SLEDAI2K and with each other were evaluated in patients. There were a significant difference between serum concentrations of sFas and IL-18 in the case and control groups (P = 0.001). There was a significant correlation between serum concentrations of sFAS and IL-18 in SLE patients (P< 0.0001, r = 0.411). The elevations of IL-18 and sFas(Apo/1-CD95) serum concentrations in SLE patients are significantly correlated.

show abstract

Section: Discussionsupporting

confidence: 95%

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

et al. 2010

View full text Add to dashboard Cite

show abstract

“…All proteins have been detected with a sensitivity about 10 3 to 10 4 -fold higher than by ELISA [45], confirming that FACTTbased assays have broad applications. Blood tests are currently being used to detect biomarkers for cardiovascular disease [46][47][48], rheumatoid arthritis [49][50][51], Alzheimer's disease [52,53], and hepatitis [54,55]. Detecting and quantitatively monitoring the serum concentrations of cytokine inhibitors or soluble cytokine receptors, as well as the clinical response of patients to treatment with cytokine antagonists, might generate important information for monitoring autoinflammatory diseases [56].…”

Section: Versatility Of Factt For Diseasesmentioning

confidence: 99%

Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood

Freudenberg

Bembas

Greene

et al. 2008

Methods

View full text Add to dashboard Cite

Many diseases are easier to treat and control when detected at an early stage of disease progression. Often, disease-related antigens or biomarkers are shed from the primary site and present in the blood. Unfortunately, there are very few tests capable of detecting these rare biomarkers in the blood. A blood test would be very useful to diagnose the disease earlier, monitor effectiveness of treatments, predict recurrence, and monitor recurrence. There is certainly a need to develop assays that are ultrasensitive, non-invasive and high-throughput. Here we describe several highly sensitive immunological assays we have developed to detect rare serum antigens. Initially we created an assay named immunodetection amplified by T7 RNA polymerase (IDAT). To enhance the effectiveness and streamline the procedure, this assay was amended to the facile amplification system termed fluorescent amplification catalyzed by T7 polymerase technique (FACTT). These assays have been used to analyze the tumor antigen HER2 and the prion protein PrP Sc . They can also be applied to other tumor markers or antigens from a variety of diseases such as cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, and hepatitis. These tests are not limited to testing only serum, but may also be applicable to detecting biomarkers in tissue, saliva, urine, cerebrospinal fluid, etc. Clearly, the FACTT-based technology represents an important step in the detection of rare molecules in fluids or tissues for a variety of diseases.

show abstract

“…Elevated content of soluble Fas antigen (sFas) and/or soluble Fas-ligand is quite often a remarkable peculiarity observed in autoimmune patient serum [15][16][17][18]. For the first time the elevated level of soluble Fas was found in patients with SLE and RA [19].…”

Section: Introductionmentioning

confidence: 98%

A possible role of Fas-ligand-mediated “reverse signaling” in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus

et al. 2009

View full text Add to dashboard Cite

Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Cited by 18 publications

References 26 publications

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood

A possible role of Fas-ligand-mediated “reverse signaling” in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus

Contact Info

Product

Resources

About